AU2003277832A8 - Humanized tissue factor antibodies - Google Patents

Humanized tissue factor antibodies

Info

Publication number
AU2003277832A8
AU2003277832A8 AU2003277832A AU2003277832A AU2003277832A8 AU 2003277832 A8 AU2003277832 A8 AU 2003277832A8 AU 2003277832 A AU2003277832 A AU 2003277832A AU 2003277832 A AU2003277832 A AU 2003277832A AU 2003277832 A8 AU2003277832 A8 AU 2003277832A8
Authority
AU
Australia
Prior art keywords
tissue factor
factor antibodies
humanized tissue
humanized
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003277832A
Other versions
AU2003277832A1 (en
Inventor
Stefan Zahn
Kristian Kjaergaard
Ivan Svendsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2003277832A1 publication Critical patent/AU2003277832A1/en
Publication of AU2003277832A8 publication Critical patent/AU2003277832A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/7454—Tissue factor (tissue thromboplastin, Factor III)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2003277832A 2002-10-31 2003-10-31 Humanized tissue factor antibodies Abandoned AU2003277832A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200201661 2002-10-31
DKPA200201661 2002-10-31
PCT/DK2003/000741 WO2004039842A2 (en) 2002-10-31 2003-10-31 Humanized tissue factor antibodies

Publications (2)

Publication Number Publication Date
AU2003277832A1 AU2003277832A1 (en) 2004-05-25
AU2003277832A8 true AU2003277832A8 (en) 2004-05-25

Family

ID=32187133

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003277832A Abandoned AU2003277832A1 (en) 2002-10-31 2003-10-31 Humanized tissue factor antibodies

Country Status (2)

Country Link
AU (1) AU2003277832A1 (en)
WO (1) WO2004039842A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064870A2 (en) * 2003-01-22 2004-08-05 Novo Nordisk A/S Radiolabelled tissue factor binding agent and the use thereof
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
WO2004110363A2 (en) * 2003-05-30 2004-12-23 Centocor, Inc. Method of inhibiting tumor growth with anti-tissue factor antibodies
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP1749536A1 (en) * 2005-08-03 2007-02-07 Thrombotargets Europe, S.L. Activated factor X stimulants as new antihemorrhagic agents for topical use
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
CN106084053B (en) 2010-06-15 2020-01-17 根马布股份公司 Human antibody drug conjugates against tissue factor
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
US11401345B2 (en) * 2017-11-27 2022-08-02 Purdue Pharma L.P. Humanized antibodies targeting human tissue factor
WO2021200131A1 (en) * 2020-03-30 2021-10-07 国立研究開発法人国立がん研究センター Antibody drug conjugate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001978A (en) * 1987-03-31 1999-12-14 The Scripps Research Institute Human tissue factor related DNA segments polypeptides and antibodies
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ES2231817T3 (en) * 1995-06-07 2005-05-16 Ortho-Mcneil Pharmaceutical, Inc. ANTI-FABRIC ANTIBODIES INTRODUCED TO CDR AND PROCEDURES FOR THE SAME USE.
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US6461610B1 (en) * 1997-07-18 2002-10-08 Novo Nordisk A/S Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
DK1069185T3 (en) * 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humanized antibody to human tissue factor (TF) and method of constructing humanized antibody
AU5081401A (en) * 2000-03-16 2001-10-03 Genentech Inc Anti-tissue factor antibodies with enhanced anticoagulant potency
PL368989A1 (en) * 2001-10-02 2005-04-04 Novo Nordisk A/S Human tissue factor antibodies
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof

Also Published As

Publication number Publication date
AU2003277832A1 (en) 2004-05-25
WO2004039842A3 (en) 2004-09-23
WO2004039842A2 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
AU2003259294A8 (en) Humanized antibodies against human 4-1bb
IL200604A0 (en) Human monoclonal antibodies against cd30
HK1077226A1 (en) Human monoclonal antibodies against cd25
EP1494693A4 (en) Cripto-specific antibodies
TWI367102B (en) Therapeutic human anti-il-1r1 monoclonal antibody
PL375405A1 (en) Antibodies
EP1572131A4 (en) Antibody therapy
IL166244A0 (en) Super humanized antibodies
EP1616881A4 (en) Anti-mpl antibodies
AU2003264009A8 (en) Humanized rabbit antibodies
IL175608A0 (en) Antibodies
IL165256A0 (en) Neutralizing human anti-igfr antibody
IL172511A0 (en) Specific human antibodies
AU2003277832A8 (en) Humanized tissue factor antibodies
GB0226878D0 (en) Antibodies
GB0325391D0 (en) Human monoclonal antibodies
GB0218234D0 (en) Antibodies
GB0218232D0 (en) Antibodies
GB0218235D0 (en) Antibodies
GB0218230D0 (en) Antibodies
HK1072381A1 (en) Cripto-specific antibodies cripto-specific
GB0203018D0 (en) Antibodies
GB0210508D0 (en) Antibodies
GB0218229D0 (en) Antibodies
GB0217742D0 (en) Novel antibodies

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase